NanoVibronix (NAOV) Peer Comparison

$2.32

$-1.78 (-43.41%)

As on 13-Jan-2026 09:30EDT

Market cap

$4 Mln

Revenue (TTM)

$3 Mln

P/E Ratio

--

P/B Ratio

0

Div. Yield

0 %

Edit

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Market cap ($ Mln)	4	20
Revenue ($ Mln)	3	1
Net Profit ($ Mln)	-3.57	-84.33
Net Margin (%)	-133.04	-11,581.34
RoE (%)	-9.14	--
Price to Earnings	--	--
Price-To-Book	0.04	1.43

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Operating Revenue	2.69	0.73
Cost of Revenue	1.88	0.36
Gross Profit	1.51	0.80
Operating Expenses	10.25	10.72
Operating Profit (EBIT)	-9.45	-10.35
Other Income	0.00	0.00
Profit before Tax	-7.27	-84.01
Provision for Tax	0.12	0.00
Profit after Tax (Net Income)	-3.57	-84.33
Minority Interest	0.00	0.00
Consolidated Profit	0.00	0.00

Liabilities ($ Mln)

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Shareholder's Funds	42.46	-77.43
Minority Interest	0.00	0.00
Non-Current Liabilities	0.28	1.08
Current Liabilities	11.64	79.49
Total Liabilities	3.63	4.97

Assets ($ Mln)

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Non-Current Assets	44.37	2.03
Current Assets	10.02	1.10
Total Assets	3.63	4.97
Total Debt*	3.17	1.70
Net Current Assets	-1.63	-78.38

Cashflow ($ Mln)

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Cash From Operating Activities	-2.52	-11.96
Cash Flow from Investing Activities	0.00	0.02
Cash from Financing Activities	0.00	3.94
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
ROCE (%)	-156.46	-188.78
ROE (%)	-9.14	-302.42
ROA (%)	-9.76	-179.55
EBIT Margin (%)	-259.37	-11,540.36
Net Margin (%)	-133.04	-11,581.34
Cash Profit Margin (%)	0.00	-0.01

Growth Ratios

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Revenue Growth (%)	-18.41	-47.20
EBIT Growth (%)	-460.71	-534.43
Net Profit Growth (%)	-15.71	-503.68
EPS Growth (%)	-2.21	-3,437.07
Book Value Growth (%)	1,212.06	-34,876.37

Valuation Ratios

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Price / Earnings	-0.05	-0.37
Price / Book Value	0.30	-22.07
Dividend Yield (%)	--	--
EV/EBITDA	0.12	-0.57
Market Cap ($ Cr)	--	--

Solvency Ratios

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	0.07	-0.01
Current Ratio	0.86	0.01
Quick Ratio	0.67	0.01
Interest Coverage	-23.73	--

Operating Efficiency Ratios

	NanoVibronix (NAOV)	Predictive Oncology (POAI)
Debtors to sales (%)	9.39	3.57
Asset Turnover	0.07	0.02
Receivable days	49.48	115.08
Inventory Days	856.25	191.55
Payable days	32.18	547.56
Cash Conversion Cycle	873.55	-240.93

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly